AbbVie (ABBV) Files for Skyrizi to Treat Crohn’s Disease in EU Posted byZacks Equity Research December 1, 2021 Leave a comment on AbbVie (ABBV) Files for Skyrizi to Treat Crohn’s Disease in EU AbbVie (ABBV) submits a regulatory application in the European Union, seeking approval for risankizumab (Skyrizi) for the treatment of Crohn’s disease.